Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia

Drug (Brand / Generic)

Ingrezza / valbenazine

Developer

Neurocrine Biosciences

Therapy Class

Vesicular monoamine transporter 2 (VMAT2) inhibitor

Current Indication

Tardive dyskinesia

Market Sector

Central nervous system (CNS)

Development Status

Approved in the US
Expand

Go Top